Related by context. All words. (Click for frequent words.) 76 multicentre randomized 75 randomized multicenter 75 Phase III randomized 75 prospective multicenter 74 phase IIb clinical 74 prospective randomized controlled 73 double blinded randomized 73 prospective randomized 72 multicenter randomized 72 NO# [002] 72 placebo controlled clinical 72 placebo controlled Phase III 72 multicentre 72 Phase Ib II 72 randomized clinical 72 multicenter Phase II 72 multicenter clinical 72 placebo controlled randomized 72 randomized placebo controlled 72 confirmatory clinical 72 randomized controlled Phase 71 multicenter 71 multicenter phase 71 phase IIa clinical 71 dose escalation trial 71 phase IIb 71 BRIM2 71 CLL8 71 Phase Ib clinical 71 TMC# C# 71 landmark ATHENA 71 randomized controlled clinical 71 BRIM3 71 multicenter randomized placebo controlled 71 multicenter randomized double 71 multicenter randomized controlled 71 Phase 2a clinical 71 LUX Lung 70 multicenter prospective 70 phase IIa 70 randomized controlled 70 CALGB 70 multicenter Phase 70 placebo controlled Phase 70 Phase 1b clinical 70 ToGA 70 ongoing Phase 1b 70 multicenter Phase III 70 randomized Phase 70 Phase IIIb clinical 70 Phase IIb clinical 70 BCIRG 70 blind randomized placebo 70 Phase Ib 70 prospective randomized placebo 69 double blinded placebo 69 placebo controlled 69 dose escalation Phase 69 multicenter placebo controlled 69 Phase 2b clinical 69 randomized Phase IIb 69 ENDEAVOR IV 69 AVADO 69 ADVANCE PD 69 Phase 2a trial 69 viral kinetic 69 active comparator 69 label multicenter 68 multicenter multinational 68 Phase Ib study 68 RE LY 68 EVEREST II 68 phase Ib 68 controlled multicenter 68 RE LY ® 68 multicenter randomized clinical 68 prospective multicenter randomized 68 ONTARGET 68 oral ridaforolimus 68 dose escalation clinical 68 phase IIIb 68 alvespimycin 68 randomized controlled multicenter 68 Phase 1b trial 68 registrational trial 68 EDEMA3 67 axitinib 67 Phase 2b study 67 ExTRACT TIMI 67 Phase 1b 67 BOLDER II 67 registrational Phase 67 EURIDIS 67 nonrandomized 67 trastuzumab emtansine T DM1 67 NCCTG 67 Phase IIIb 67 prospective randomized multicenter 67 randomized double 67 TG MV 67 Phase 2b 67 dose dose escalation 67 dose escalation study 67 assessing T DM1 67 randomized blinded placebo 67 Phase 1a 67 PRECiSE 67 pertuzumab 67 Phase 1a clinical 67 Phase Ia 67 Phase IIa clinical 67 Phase III VISTA 67 randomized Phase 2b 67 blinded randomized 66 phase 2a 66 Phase IIb trial 66 TAXUS ATLAS 66 Phase IIa trial 66 EchoCRT 66 pharmacokinetic PK 66 randomized multicenter trial 66 SPIRIT FIRST 66 ENESTnd 66 SPIRIT III 66 pharmacokinetics PK 66 Amrubicin 66 Phase III randomized controlled 66 relapsed refractory multiple myeloma 66 rALLy clinical trial 66 EORTC 66 Taxotere ® 66 TAXUS V 66 blind randomized 66 sunitinib malate 66 NSABP B 66 nab paclitaxel 66 mCRC 66 ZACTIMA 66 TAXUS IV 66 phase IIb study 66 bendamustine 66 metastatic HRPC 66 randomized 66 SPIRIT IV 66 randomized blinded 66 randomized multicentre 65 Phase III clinical 65 label dose escalation 65 Phase 2a 65 evaluating tivozanib 65 blinded randomized placebo controlled 65 NSABP 65 pivotal Phase III 65 IMA# 65 Phase 2b trial 65 TRITON TIMI 65 prospective multicentre 65 subanalysis 65 SUCCEED trial 65 Phase #b/#a clinical 65 Carotid Revascularization Endarterectomy vs. 65 HGS# 65 Phase #/#a 65 Phase III placebo controlled 65 phase IIb trial 65 phase Ib clinical 65 HCV SPRINT 65 ROCKET AF 65 satraplatin Phase 65 ABCSG 65 Val HeFT 65 afatinib 65 multicentre randomized double 65 neratinib 65 enzastaurin 65 PERSEUS 65 COMFORT II 65 PFO migraine 65 confirmatory Phase III 65 AVERROES 65 Phase III 65 crizotinib PF # 65 sunitinib 65 CHAMPION PCI 65 teriflunomide 65 Phase IIa 65 SWOG 65 AVOREN 65 Randomized Phase II 64 label multicenter randomized 64 evaluating Actimmune 64 APEX PD 64 Phase IIb III 64 evaluating REVLIMID 64 ASTEROID 64 multicenter study 64 CALGB # [002] 64 Sym# 64 ILLUMINATE 64 BR.# 64 AIM HIGH 64 pivotal bioequivalence 64 sorafenib Nexavar 64 pharmacokinetic PK study 64 fosbretabulin 64 Edge STudy 64 MERLIN TIMI 64 Tarceva TM 64 RADIANT 64 dose escalation 64 EDEMA4 64 REALITY Trial 64 CLARITY TIMI 64 docetaxel Taxotere R 64 neoadjuvant 64 plus dexamethasone 64 randomized multicenter Phase III 64 Phase III pivotal 64 Sorafenib HCC Assessment 64 blind randomized controlled 64 DASISION 64 Prostate AdenoCarcinoma Treatment 64 masked placebo controlled 64 Phase IIb 64 Phase IIIb study 64 tanespimycin 63 GetGoal Phase III 63 phase III ACCLAIM 63 ACTEMRA TM 63 CARE HF 63 Clinical Antipsychotic Trials 63 RIBBON 63 treatment naive genotype 63 double blind placebo 63 ganetespib 63 label multicenter Phase 63 AIR CF2 63 BARI 2D 63 noninferiority 63 MEND CABG 63 CAMMS# 63 CUSTOM II 63 prospectively defined 63 APPRAISE 63 Phase 2b kidney transplant 63 AIR CF1 63 CLARITY study 63 RE LY trial 63 ZYBRESTAT fosbretabulin 63 multiple ascending dose 63 RIO Lipids 63 single ascending dose 63 PRE SURGE 63 adecatumumab 63 Betaferon ® 63 ascending dose 63 Prospective Randomized 63 HCV RESPOND 2 63 Stenting Trial CREST 63 HER2 positive metastatic breast 63 docetaxel chemotherapy 63 ELACYT 63 relapsed MM 63 MabCampath 63 NEVO RES 63 NCT# ClinicalTrials.gov 63 recurrent malignant glioma 63 EXPLORE Xa 63 Phase III randomized placebo 63 pharmacodynamics PD 63 Cloretazine 63 PROSTVAC TM 63 Phase IIb trials 63 ASCEND HF 63 dose cohorts 63 YONDELIS 63 APTIVUS 63 pomalidomide 63 vandetanib 63 pivotal Phase 63 ANCHOR trial 63 fidaxomicin Phase 3 63 registrational 63 Phase III multicenter 63 EOquin TM 63 Quinamed 63 multicentre randomized controlled 62 recurrent GBM 62 prospective observational 62 ACTEMRA 62 Onrigin 62 Randomized Evaluation 62 randomized controlled clinical trials 62 oral rivaroxaban 62 ORAL Sync 62 RoACTEMRA 62 multicenter trials 62 Carfilzomib 62 Imprime PGG 62 oral deforolimus 62 Multicenter 62 PROSTVAC ® 62 Randomized Phase 62 Gynecologic Oncology Group 62 Augment Injectable 62 ABSORB trial 62 safety tolerability pharmacokinetic 62 mapatumumab 62 darunavir ritonavir 62 Denufosol 62 mRCC 62 trabectedin 62 ECASS 62 Phase Ib IIa 62 HuMax EGFr 62 Tanespimycin 62 mg/m2 cohort 62 sorafenib 62 Phase 1b dose escalation 62 vidofludimus 62 elotuzumab 62 olaparib 62 CIMZIA TM certolizumab pegol 62 brivaracetam 62 huC# DM4 62 HGS ETR1 62 chlorambucil 62 elacytarabine 62 trabedersen 62 refractory chronic lymphocytic 62 ENDEAVOR III 62 LUMINATE 62 AVASTIN 62 PRIMO CABG 62 subgroup analyzes 62 HGS ETR2 62 JAK inhibitor 62 CIMZIA TM 62 Allovectin 7 ® 62 sorafenib Nexavar ® 62 Combination REOLYSIN R 62 tesmilifene 62 Radiation Therapy Oncology 62 Prostate Lung Colorectal 62 SCH # 62 PD LID 62 CA4P 62 gemcitabine carboplatin 62 multicenter randomized Phase III 62 viral kinetics 62 ABSORB clinical 62 randomized trials 62 trials RCTs 62 pemetrexed 62 galiximab 62 Pirfenidone 62 decitabine 62 HPTN 62 Afatinib 62 CRLX# 62 dabigatran etexilate 62 metastatic hormone refractory 62 randomized crossover 62 ritonavir boosted 62 lintuzumab 62 Phase III confirmatory 62 IMPACT IMmunotherapy 62 FOLOTYN ® 62 AEGR 62 multicenter randomized Phase 61 Phase IIB 61 DU #b 61 FOLFOX 61 XL# SAR# 61 Ixempra 61 multinational multicenter randomized 61 FOLFIRI 61 Cloretazine ® 61 Randomized controlled 61 randomized clinical trials 61 LEXIVA r 61 interferon gamma 1b 61 forodesine 61 dosing cohorts 61 clinical pharmacology studies 61 PRECISE 61 deforolimus 61 ICON7 61 ixabepilone 61 evaluating Nexavar 61 controlled multicenter Phase 61 chemotherapeutic regimen 61 randomized discontinuation trial 61 UPLYSO 61 TRANSFORMS 61 recurrent glioblastoma multiforme 61 Telatinib 61 HORIZONS AMI trial 61 relapsed multiple myeloma 61 ADAGIO study 61 posaconazole 61 Pertuzumab 61 MAGE A3 ASCI 61 Phase 1b clinical trials 61 CANCIDAS 61 Bowel Project NSABP 61 ACUITY trial 61 refractory metastatic colorectal cancer 61 receptor tyrosine kinase inhibitor 61 placebo controlled multicenter 61 Traficet EN 61 Azedra 61 icatibant 61 TEMSO 61 European Sepsis Trial 61 metastatic renal cell carcinoma 61 mCRC patients 61 OLYMPIA registry 61 MIVI III 61 iniparib 61 placebo controlled dose escalation 61 IMGN# 61 BOLDER 61 velafermin 61 relapsed myeloma 61 relapsing multiple sclerosis 61 riociguat 61 clinical trial 61 CIMZIA ™ 61 BRAF inhibitor 61 pazopanib 61 pharmacodynamics 61 blind multicenter 61 amrubicin 61 gemcitabine 61 hepatocellular carcinoma HCC 61 KRAS mutations occur 61 ZD# [001] 61 CHARISMA trial 61 lorvotuzumab mertansine 61 CAPRISA 61 FOLPI 61 virus HCV protease inhibitor 61 everolimus eluting stent 61 Xelox 61 Dacogen injection 61 temsirolimus 61 azacitidine 61 eribulin mesylate 61 Acute Myocardial Infarction 61 IIa trial 61 preclinical efficacy 61 vorinostat 61 CURRENT OASIS 7 61 INCB# [001] 61 number NCT# ClinicalTrials.gov 61 Phase 2b randomized 61 multicentre study 61 ISEL 61 VELCADE melphalan 61 Aplidin 61 angiogenesis inhibitor 61 substudy 61 PARTNER Trial 61 Intervention Effectiveness 61 multicentre prospective 61 ACCORD Lipid 61 SABCS 61 Deforolimus 61 GOUT 61 ascending dose study 61 Group B CALGB 61 REVLIMID lenalidomide 61 Ozarelix 61 Aflibercept 61 Hepatocellular Carcinoma HCC 61 DAPT Study 61 vicriviroc 61 aflibercept 61 Pivotal Trial 61 PRESEPT 61 Phase Ib clinical trials 61 plus prednisone 61 pegylated liposomal doxorubicin 61 Taxotere R 61 huN# DM1 61 PIX# [002] 60 Phase #b/#a 60 metastatic colorectal cancer 60 carboplatin paclitaxel 60 Enzastaurin 60 phase IIb III 60 HORIZONS AMI 60 Aplidin R 60 Elagolix 60 EMPHASIS HF trial 60 Phase III AFFIRM 60 PreCISe 60 capecitabine Xeloda R 60 CLORETAZINE TM VNP#M 60 RSD# oral 60 solithromycin 60 placebo controlled trials 60 blind randomized multicenter 60 randomized controlled trial 60 Acute Ischemic Stroke 60 PROPEL 60 Initiated Phase 60 evaluable patients 60 liposomal formulation 60 depsipeptide 60 imetelstat 60 Daclizumab 60 treatment naïve genotype 60 dose regimens 60 Cloretazine R VNP#M 60 Glufosfamide 60 lumiliximab 60 Group RTOG 60 Clolar ® 60 unblinding 60 PSMA ADC 60 retrospective observational study 60 Fludara 60 CUSTOM III 60 Irinotecan 60 BAY #-# 60 ACRIN 60 ofatumumab 60 Phase III ALLEGRO 60 biliary tract cancer 60 reslizumab 60 blinded randomized controlled 60 Virulizin ® 60 Folfox 60 Phase III psoriasis 60 placebo controlled studies 60 NVA# 60 ENDEAVOR IV clinical 60 CBLC# 60 TELCYTA 60 ORMD 60 Screening Trial 60 peginterferon alfa 2b 60 sapacitabine 60 CYPHER ® Sirolimus eluting 60 NCIC CTG 60 fostamatinib 60 unique alkylating agent 60 Pemetrexed 60 AEG# 60 STRIDE PD 60 Cardiac Allograft Rejection 60 glufosfamide 60 SYMMETRY trial 60 Arimidex Tamoxifen Alone 60 DAPT 60 sunitinib Sutent 60 GV# [001] 60 placebo controlled clinical trials 60 OncoVEX GM CSF 60 PDX pralatrexate 60 Myocardial Infarction Study 60 Long Lesion 60 pharmacodynamic effects 60 CYPHER ® Stent 60 Endovascular Valve Edge 60 PROVENGE sipuleucel T 60 BiTE antibody MT# 60 AIR CF3 60 VNP#M 60 prospective nonrandomized 60 XELOX 60 Phase #/#a trial 60 ATTRACT 60 evaluating T DM1 60 IMPROVE IT 60 LCP AtorFen 60 RE SURGE 60 melphalan prednisone 60 TO AVOID PREGNANCY WHILE 60 fluvastatin 60 Phase 2b monotherapy 60 stage IIIB 60 FOLFIRI chemotherapy 60 Initiate Phase 60 vascular disrupting agent 60 International Verapamil SR 60 obatoclax 60 docetaxel 60 Randomised 60 boosted protease inhibitor 60 ALLEGRO 60 dose cohort 60 EFAPROXYN 60 CoFactor 60 AERAS-#/Crucell Ad# 60 Vectibix panitumumab 60 Zenvia Phase III 60 MIVI TRUST 60 EndoTAG TM -1 60 INSPIRE Trial Phase III 60 Blinatumomab 60 AIR2 Trial 60 DermaVir Patch 60 safety tolerability pharmacokinetics 60 CA9 SCAN 60 seliciclib 60 neoadjuvant treatment 60 acyclovir Lauriad R 60 NEVO TM 60 docetaxel Taxotere ® 60 edoxaban 60 fidaxomicin Phase 60 Hsp# Inhibitor 60 Board DSMB 60 DSMB 60 NCCTG N# 60 tolerated dose MTD 60 Oral Fingolimod 60 pharmacokinetic studies 60 pharmacodynamic profile 60 anticancer compound 60 randomized #:# 60 bosentan 60 comparing alemtuzumab 60 rALLy trial 60 MGd 60 anti arrhythmic drug 60 refractory CLL 60 ACCLAIM 60 IFN alfa 60 tocilizumab 60 PRT# 60 National Surgical Adjuvant 60 CONQUER OB 60 ASCO abstract 60 bevacizumab Avastin 59 subcutaneously administered 59 Degarelix 59 IIa clinical 59 non inferiority 59 angiotensin receptor blocker ARB 59 RECORD1 59 MIRCERA 59 CYT# 59 Trandolapril 59 paclitaxel poliglumex 59 Phase III ThermoDox 59 ZOLINZA 59 cilengitide 59 Randomized Study 59 PXD# 59 Phase III metastatic melanoma 59 RG# ITMN 59 Renal Cell Carcinoma RCC 59 CR# vcMMAE 59 Pegasys ® 59 Multiple Ascending Dose 59 CHAMPION PLATFORM 59 GAMMAGARD 59 HCD# [002] 59 IL# PE#QQR 59 RenalGuard System TM 59 low dose cytarabine 59 MIST II 59 glatiramer acetate 59 CTRC AACR San Antonio 59 farletuzumab 59 Omacetaxine 59 Ranolazine 59 concurrent chemoradiation 59 dosage regimens 59 cediranib 59 VITAL Trial 59 Proxinium TM 59 observer blinded randomized 59 NATRECOR R 59 CATIE AD 59 evaluating carfilzomib 59 cisplatin vinorelbine 59 relapsed MCL 59 comparing XIENCE V 59 Phase IIb randomized 59 Doxil ® 59 dose escalation phase 59 evaluating Vectibix 59 daily Infergen 59 unblinded 59 zalutumumab 59 standard chemotherapy regimen 59 heavily pretreated 59 advanced unresectable 59 TAXUS VI 59 IMC A# 59 refractory multiple myeloma 59 stage IIIb IV 59 IIa clinical trial 59 Pivotal Phase III 59 CTA# Injection 59 ascending doses 59 metastatic CRC 59 TORISEL 59 trastuzumab DM1 T DM1 59 pegylated interferon alfa 2b 59 PANVAC VF 59 ORENCIA ® 59 RTOG 59 Neoadjuvant 59 thorough QT 59 pharmacodynamic PD 59 CORD II 59 MADIT II 59 Tracleer R 59 resminostat 59 chemotherapy FOLFOX 59 oral Xeloda 59 advanced metastatic renal 59 AVAiL 59 recurrent NSCLC 59 trodusquemine 59 tenofovir emtricitabine 59 NEO3 59 doxorubicin docetaxel 59 Zemplar Capsules 59 platinum refractory 59 Triapine 59 KRAS wild 59 denufosol 59 XIENCE V Everolimus Eluting 59 ticagrelor 59 superficial bladder cancer 59 SUTENT ® 59 talabostat 59 TYKERB 59 advanced NSCLC 59 eculizumab 59 ASSERT trial 59 Ceplene/IL-2 59 ponatinib 59 bevacizumab Avastin ® 59 confirmatory Phase 3 59 RE MODEL 59 LITHE 59 Temsirolimus 59 TASKi2 59 regorafenib 59 designated HVTN 59 histone deacetylase HDAC inhibitor 59 PCI ExTRACT TIMI 59 evaluating Xcytrin 59 pharmacokinetic pharmacodynamic 59 metastatic castration resistant 59 Zalypsis 59 SCCHN 59 REVIVE Diabetes 59 HYVET 59 desvenlafaxine succinate 59 PREVENT IV 59 AP# [003] 59 erlotinib Tarceva ® 59 antitumor activity 59 ASSERT 59 R# #mg BID 59 cathepsin K inhibitor 59 gefitinib 59 Pharmacokinetic 59 Plicera 59 Phase 2b Study 59 PREZISTA r 59 plus COPEGUS 59 COPERNICUS 59 Tesetaxel 59 TTF Therapy 59 oral prodrug 59 palifosfamide 59 Adalimumab 59 bevacizumab 59 cariprazine 59 sirolimus eluting stent 59 By JENNIFER LEARN 59 ThermoDox 59 μg dose 59 dosing cohort 59 INC# 59 Safinamide 59 Bowel Project 59 Phase III trials 59 pegylated interferon alpha 59 STENT 59 Alocrest 59 mertansine 59 #mg QD [002] 59 Genasense ® 59 Apixaban 59 MLN# 59 PEG SN# 59 PEGylated interferon beta 1a 59 metastatic RCC 59 Vicinium TM 59 PROTECT AF 59 PI3K/Akt pathway inhibitor 59 PROMUS Element Stent 59 MADIT CRT 59 TLK# 59 Dasatinib 59 FOLOTYN 59 Prospective Randomized Trial 59 iclaprim 59 trastuzumab Herceptin R 59 fallopian tube cancers 59 beta2 agonist 59 VADT 59 Clinical Outcomes Utilizing Revascularization 59 chemoradiotherapy 59 multiple myeloma MM 59 BioNumerik 59 ACTIVE W 59 compound INCB# 59 prucalopride 59 Pivotal Study 59 sorafenib tablets 59 maximally tolerated dose 59 paclitaxel eluting stent 59 bazedoxifene conjugated estrogens 59 Nexavar ® 59 NEVO 59 Pivotal Phase 59 sNDA submission 59 telaprevir dosed 59 Sibutramine Cardiovascular Outcomes 59 analgesic efficacy 59 Vectibix monotherapy 59 CALERIE 59 KRN# 59 blinatumomab 59 AZILECT R 59 Telmisartan 59 HuMax CD4 59 dasatinib Sprycel ® 59 novel VDA molecule 59 Sorafenib 59 Certican 59 ELCAP 59 milatuzumab 59 NSABP C 59 ASA# 59 PROPEL trial 59 SIR Spheres 59 gemcitabine chemotherapy 59 Randomized Double blind 58 Dapagliflozin 58 APEX AMI trial 58 canakinumab 58 Ovarian Cancer Screening 58 RECIST Response Evaluation Criteria 58 nitazoxanide 58 leukemia CLL 58 Teriflunomide 58 T DM1 58 gemcitabine Gemzar ® 58 NICE SUGAR 58 intravenous belinostat 58 CYPHER Stent 58 Clolar 58 free survival PFS 58 Tyrima 58 cetuximab Erbitux 58 Elvitegravir 58 PRIMO CABG2 58 XIENCE V Stent System 58 KRAS status 58 cisplatin gemcitabine 58 Aclidinium 58 Phase IIa trials 58 PET FROM 58 tolevamer 58 Pharmacokinetics PK 58 Annamycin 58 Randomized 58 oral FTY# 58 Ophena TM 58 entinostat 58 prospectively randomized 58 Ceflatonin 58 Maximum Tolerated Dose MTD 58 CML CP 58 RE COVER 58 papillary renal cell carcinoma 58 Pharmacokinetic Study 58 Actemra 58 5 fluorouracil leucovorin 58 EndoTAGTM 1 58 SUTENT 58 dacarbazine 58 carboplatin 58 Phase III Trial 58 REYATAZ r 58 tolerability 58 COU AA 58 Seliciclib 58 sequential dose escalation 58 eprotirome 58 TACI Ig 58 adjuvant colon cancer 58 TAXUS Liberte Stent 58 evaluating satraplatin plus 58 NXL# 58 comparator arm 58 neoadjuvant chemotherapy 58 basal bolus regimen 58 generation Hsp# inhibitor 58 abacavir lamivudine 58 blinded placebo controlled 58 Afinitor everolimus 58 PRTX 58 retaspimycin 58 bosutinib 58 OMP #M# 58 factorial design 58 ENDEAVOR 58 ZYBRESTAT 58 AZILECT ® 58 blind placebo controlled 58 ADMIRE HF 58 FAME Study 58 SORT OUT III 58 non squamous NSCLC 58 Phase III Clinical Trial 58 TMC# [002] 58 Alpharadin 58 NEVO ™ 58 FOLFOX6 chemotherapy regimen 58 II Clinical Trial 58 antibody MAb 58 goserelin 58 Resolute DES 58 Phase III Clinical Trials 58 MelaFind pivotal 58 LHRH receptor positive 58 estramustine 58 Multicentre 58 REMINYL ® 58 TASQ 58 dasatinib 58 LCP Tacro 58 orBec 58 intravenous dosing 58 adult chronic ITP 58 null responder HCV 58 HCV protease inhibitor 58 rNAPc2 58 tremelimumab 58 RG# [001] 58 Cimzia TM 58 PSN# [002] 58 GRAVITAS trial 58 PROVENGE ® 58 mTOR inhibitor 58 biologic therapy 58 intermittent dosing 58 resistant ovarian cancer 58 MEND CABG II 58 ARCOXIA 58 pan HDAC inhibitor 58 Randomized Double Blind Placebo 58 ACCEDE 58 PHASE III 58 HeFT 58 TOLAMBA 58 ofatumumab HuMax CD# 58 bicifadine 58 Proellex TM 58 Xeloda ® 58 non nucleoside inhibitor 58 Val MARC 58 follicular NHL 58 recurrent metastatic 58 radiation sensitizer 58 RezularTM 58 RRMS patients 58 VELCADE 58 virologic 58 HCV NS5B polymerase 58 ENGAGE AF TIMI 58 bevacizumab Avastin R 58 sulodexide 58 everolimus eluting stents 58 recurrent ovarian cancer 58 PKC# 58 daunorubicin 58 SANTE 58 pegylated interferon 58 cutaneous T cell 58 CYPHER R Stent 58 monotherapy 58 Phase #/#a clinical 58 mGluR5 negative 58 lupus nephritis